Three Hats
Clinician. Wall Street shark. Biotech founder.
Most people wear one hat. Dr. Gupta wears all three. And it matters. You can’t just make a drug. You have to sell the dream to investors who want returns while navigating regulators who want safety and doctors who want it to work. Really work. It’s a triad. Break one link and the chain snaps.
“You can’t bring products to market successfully by thinking only about one group. It has to be the clinician, the patient, and the investor.”
He’s not theorizing. He’s done the paperwork. The market dynamics, the investor sentiment, the red tape. It all connects.
The Silent Gap
Kidneys don’t make headlines like cancer. They’re quiet. And the market treats them that way. Low awareness. Low urgency. Reimbursement is a headache.
So the innovation dries up. Unicycive sees this as an opening. A huge one. But you don’t just parachute in with a pill. You start early. With the physicians. With the opinion leaders. If you don’t partner with them before you launch you’re already behind. It’s about trust. Built long before the first trial ends.
Leading The Way
Culture isn’t a poster in the break room. You pick the team and you set the tone. Early on. You choose people who bleed the same mission as you.
When things go south—and they do—he owns it. Not the other way around. You take the heat for setbacks. That’s the trade. You get courage, creativity, transparency in return. People need to know it’s safe to fail. Really safe. If you shoot the messenger nobody sends news anymore. Just bad data. Or worse. No data at all.
The Machine Helper
Doctors spend too much time typing. Documenting. Filling boxes. It eats their day. It kills the empathy. Why did they go to med school? To hold a hand, not fill out a form.
AI can strip away the admin bloat. Automate the history taking. Clear the documentation backlog. Suddenly the doctor has time. For the patient. The human part. The reason anyone cared enough to wear a white coat.
And on the business side? He’s using AI for dirty work. Competitive intel. Finding where the patients are so marketing doesn’t burn cash on empty seats. It’s efficient. It’s cold. It’s necessary.
Do we really have a choice though?
